{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:11:36Z","timestamp":1779203496530,"version":"3.51.4"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite recent advances in cardiovascular pharmacotherapy, prevention and treatment of many cardiovascular diseases remain limited with a clear need for more effective and safer pharmacological strategies. Here, we summarize the most relevant advances in cardiovascular pharmacotherapy in 2025, including the approval of four new drugs (aficamten, etripamil, lerodalcibep, and plozasiran), the label expansions for five already approved drugs, and the results of major randomized clinical trials with already approved drugs, including those that met the prespecified primary endpoints (positive trials) representing new pharmacological options for cardiovascular diseases, those with neutral or negative results, which did not confirm the primary endpoints and the withdrawal from the US market of Andexanet-alfa for safety concerns. Finally, we present the most promising experimental cardiovascular drugs currently being investigated in ongoing Phase 2 and 3 clinical trials.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvag016","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:44:23Z","timestamp":1775216663000},"page":"147-166","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular pharmacotherapy in 2025"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-7758","authenticated-orcid":false,"given":"Juan","family":"Tamargo","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n , Avenida Ram\u00f3n y Cajal s\/n, Madrid 29040 ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[{"name":"Institute of Clinical Science, Oslo University , Oslo 0318 ,","place":["Norway"]},{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute , Stockholm 18288 ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Ambrosio","sequence":"additional","affiliation":[{"name":"Center for Clinical and Translational Research\u2014CERICLET, Department of Medicine, University of Perugia , Perugia 06156, Italy"},{"name":"National Institute for Cardiovascular Research\u2013INRC , Via Irnerio, 48, 40126 Bologna ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[{"name":"Medical and Surgical Sciences Deparment, University of Bologna-IRCCS AOU S. Orsola , Bologna 40138 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7839-1361","authenticated-orcid":false,"given":"Elisabetta","family":"Cerbai","sequence":"additional","affiliation":[{"name":"Department Neurofarba, Section of Pharmacology and Toxicology, University of Florence , Firenze 50121 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gheorghe A","family":"Dan","sequence":"additional","affiliation":[{"name":"Romanian Academy of Scientists, Carol Davila University of Medicine , Bucharest 050474 , Rumania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[{"name":"Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT) , Feldkirch 6800 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Ferdinandy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Semmelweis University , Budapest 1089 ,","place":["Hungary"]},{"name":"Pharmahungary Group , Szeged 6722 ,","place":["Hungary"]},{"name":"Center for Pharmacology and Drug Research & Development, Semmelweis University , Budapest 1085 ,","place":["Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus 8200 ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Aarhus 8200 ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Klingenberg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, KerckhoffHeart and Thorax Center , Bad Nauheim 61231 ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao","family":"Morais","sequence":"additional","affiliation":[{"name":"ciTechCare\u2014Center for Innovative Care and Health Technology, Polytechnic University of Leiria , Leira 2414-016 ,","place":["Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Parker","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Unit, University of Sheffield , Sheffield S5 7AU ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, LUM University , Casamassima, Bari 70010 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5146-0099","authenticated-orcid":false,"given":"Patrick","family":"Sulzgruber","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Medical University of Vienna , Vienna 1090 ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Grete","family":"Semb","sequence":"additional","affiliation":[{"name":"Preventive Cardio-Rheuma Clinic, Division of Research and Innovation, REMEDY centre, Diakonhjemmet Hospital , Oslo 0370 ,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Sossalla","sequence":"additional","affiliation":[{"name":"Medical Clinic I, Cardiology and Angiology, Gie\u00dfen & Department of Cardiology, Campus Kerckhoff, Bad Nauheim and Justus-Liebig-Universit\u00e4t, 35392 Gie\u00dfen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Kaski","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Sciences Research Institute, St.George\u2019s, University of London , Cranmer Terrace, London SW17 0RE ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-117X","authenticated-orcid":false,"given":"Dobromir","family":"Dobrev","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Medical Faculty, University Duisburg-Essen , Essen 45122 , ; Montr\u00e9al, Quebec H1T1C8","place":["Germany"]},{"name":"Department of Medicine, Montreal Heart Institute and Universit\u00e9de Montr\u00e9al ,","place":["Canada"]},{"name":"Department of Integrative Physiology, Baylor College of Medicine , Houston, TX 77030 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,5]]},"reference":[{"key":"2026051910571102200_pvag016-B1","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0140-6736(25)00333-2","article-title":"Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial","volume":"405","author":"Veltkamp","year":"2025","journal-title":"Lancet"},{"key":"2026051910571102200_pvag016-B3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2503678","article-title":"Early tirofiban infusion after intravenous thrombolysis for stroke","volume":"393","author":"Tao","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa2508808","article-title":"Early discontinuation of aspirin after PCI in low-risk acute myocardial infarction","volume":"393","author":"Tarantini","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa2503867","article-title":"Intravenous tenecteplase before thrombectomy in stroke","volume":"393","author":"Qiu","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B6","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1056\/NEJMoa2413344","article-title":"Alteplase for posterior circulation ischemic stroke at 4.5 to 24 hours","volume":"392","author":"Yan","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jchf.2024.11.015","article-title":"Beta-blockers and long-term mortality in takotsubo syndrome: results of the multicenter GEIST registry","volume":"13","author":"Raposeiras-Roubin","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026051910571102200_pvag016-B8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMoa2415471","article-title":"Digitoxin in patients with heart failure and reduced ejection fraction","volume":"393","author":"Bavendiek","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B11","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B12","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"2026051910571102200_pvag016-B13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa2512761","article-title":"Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk","volume":"394","author":"Marston","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B16","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","article-title":"Targeting APOC3 with olezarsen in moderate hypertriglyceridemia","volume":"393","author":"Bergmark","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B17","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1161\/CIRCULATIONAHA.124.073233","article-title":"Efficacy and safety of inclisiran in adolescents with genetically confirmed homozygous familial hypercholesterolemia: results from the double-blind, placebo-controlled part of the ORION-13 randomized trial","volume":"151","author":"Wiegman","year":"2025","journal-title":"Circulation"},{"key":"2026051910571102200_pvag016-B18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B20","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa2508170","article-title":"Sotatercept for pulmonary arterial hypertension within the first year after diagnosis","volume":"393","author":"McLaughlin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B21","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","article-title":"Sotatercept in patients with pulmonary arterial hypertension at high risk for death","volume":"392","author":"Humbert","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B23","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500158","article-title":"Cardiac effects of dapagliflozin in people with chronic kidney disease","volume":"4","author":"Bartholdy","year":"2025","journal-title":"NEJM Evid"},{"key":"2026051910571102200_pvag016-B24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"EMPA-KIDNEY Collaborative Group","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jacc.2025.05.033","article-title":"Sodium-glucose cotransporter 2 inhibitor with and without an aldosterone antagonist for heart failure with preserved ejection fraction: the SOGALDI-PEF trial","volume":"86","author":"Ferreira","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026051910571102200_pvag016-B26","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/13543784.2022.2113374","article-title":"Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline","volume":"31","author":"Tamargo","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"2026051910571102200_pvag016-B27","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/cpdd.1383","article-title":"Pharmacokinetics and pharmacodynamics of etripamil, an intranasally administered, fast-acting, nondihydropyridine calcium channel blocker","volume":"13","author":"Ip","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026051910571102200_pvag016-B29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(23)00776-6","article-title":"Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial","volume":"402","author":"Stambler","year":"2023","journal-title":"Lancet"},{"key":"2026051910571102200_pvag016-B30","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","article-title":"Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial","volume":"9","author":"Klug","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026051910571102200_pvag016-B31","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","article-title":"Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial","volume":"44","author":"Raal","year":"2023","journal-title":"Eur Heart J"},{"key":"2026051910571102200_pvag016-B32","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B33","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"2026051910571102200_pvag016-B34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B35","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jacc.2025.06.058","article-title":"Influence of type 2 diabetes on the effects of tirzepatide in patients with heart failure and a preserved ejection fraction with obesity: a prespecified stratification-based analysis","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026051910571102200_pvag016-B36","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","article-title":"Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT trial","volume":"85","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026051910571102200_pvag016-B37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1474-4422(24)00519-2","article-title":"Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study","volume":"24","author":"van de Munckhof","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026051910571102200_pvag016-B38","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/S0140-6736(25)01571-5","article-title":"Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial","volume":"406","author":"Khan","year":"2025","journal-title":"Lancet"},{"key":"2026051910571102200_pvag016-B39","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa2507980","article-title":"Early withdrawal of aspirin after PCI in acute coronary syndromes","volume":"393","author":"Guimar\u00e3es","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2509688","article-title":"Antithrombotic therapy after successful catheter ablation for atrial fibrillation","volume":"394","author":"Verma","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jamaneurol.2025.0285","article-title":"Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation: a pragmatic, response-adaptive randomized clinical trial","volume":"82","author":"Warach","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026051910571102200_pvag016-B42","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.jacc.2025.08.041","article-title":"Twice-daily clopidogrel vs ticagrelor to reduce short-term major adverse cardiovascular events after primary percutaneous coronary intervention: the TADCLOT trial","volume":"86","author":"Hakeem","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026051910571102200_pvag016-B43","doi-asserted-by":"publisher","first-page":"ehaf652","DOI":"10.1093\/eurheartj\/ehaf652","article-title":"Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial","author":"Kang","year":"2025","journal-title":"Eur Heart J"},{"key":"2026051910571102200_pvag016-B44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B45","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/cvr\/cvae191","article-title":"Optical coherence tomography assessment of the impact of colchicine on non-culprit coronary plaque composition after myocardial infarction","volume":"121","author":"Psaltis","year":"2025","journal-title":"Cardiovasc Res"},{"key":"2026051910571102200_pvag016-B46","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1056\/NEJMoa2405923","article-title":"Routine spironolactone in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jama.2025.21358","article-title":"Metformin to improve walking performance in lower extremity peripheral artery disease: the PERMET randomized clinical trial","volume":"335","author":"McDermott","year":"2025","journal-title":"JAMA"},{"key":"2026051910571102200_pvag016-B48","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1001\/jama.2025.3833","article-title":"Intravenous ferric carboxymaltose in heart failure with iron deficiency: the FAIR-HF2 DZHK05 randomized clinical trial","volume":"333","author":"Anker","year":"2025","journal-title":"JAMA"},{"key":"2026051910571102200_pvag016-B49","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa2504735","article-title":"Beta-blockers after myocardial infarction without reduced ejection fraction","volume":"393","author":"Ibanez","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B50","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJMoa2512686","article-title":"Beta-blockers after myocardial infarction with normal ejection fraction","volume":"394","author":"Kristensen","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B51","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(25)01665-4","article-title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"406","author":"Butler","year":"2025","journal-title":"Lancet"},{"key":"2026051910571102200_pvag016-B52","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(25)01682-4","article-title":"Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials","volume":"406","author":"Zannad","year":"2025","journal-title":"Lancet"},{"key":"2026051910571102200_pvag016-B53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.125.077603","article-title":"Cardiac allograft vasculopathy inhibition with alirocumab: the CAVIAR trial","volume":"153","author":"Fearon","year":"2026","journal-title":"Circulation"},{"key":"2026051910571102200_pvag016-B54","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(25)01633-2","article-title":"Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial","volume":"406","author":"Verma","year":"2025","journal-title":"Lancet"},{"key":"2026051910571102200_pvag016-B55","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa2505927","article-title":"Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy","volume":"393","author":"Desai","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051910571102200_pvag016-B56","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/CIRCULATIONAHA.125.076575","article-title":"Dapagliflozin in patients hospitalized for heart failure: primary results of the DAPA ACT HF-TIMI 68 randomized clinical trial and meta-analysis of sodium-glucose cotransporter-2 inhibitors in patients hospitalized for heart failure","volume":"152","author":"Berg","year":"2025","journal-title":"Circulation"},{"key":"2026051910571102200_pvag016-B57","doi-asserted-by":"crossref","first-page":"10717","DOI":"10.3390\/ijms262110717","article-title":"Zilebesiran as an innovative siRNA-based therapeutic approach for hypertension: emerging perspectives in cardiovascular medicine","volume":"26","author":"Morosan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026051910571102200_pvag016-B58","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1001\/jama.2026.0287","article-title":"Data on 3 new GLP-1 drugs for weight loss that may be approved this year","volume":"335","author":"Rubin","year":"2026","journal-title":"JAMA"},{"key":"2026051910571102200_pvag016-B59","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/ehjcvp\/pvae013","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023","volume":"10","author":"Tamargo","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051910571102200_pvag016-B60","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ehjcvp\/pvad034","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022","volume":"9","author":"Tamargo","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051910571102200_pvag016-B61","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/ehjcvp\/pvaf012","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024","volume":"11","author":"Tamargo","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag016\/67787356\/pvag016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/3\/147\/67787356\/pvag016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/3\/147\/67787356\/pvag016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:57:22Z","timestamp":1779202642000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/3\/147\/8586834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,5]]},"references-count":61,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4,5]]},"published-print":{"date-parts":[[2026,5,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag016","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,5]]}}}